R-Afatinib is an afatinib isomer. Afatinib is an orally active and irreversible dual-specificity inhibitor of the ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM, and 14 nM against EGFRwt, EGFRL858R, EGFRL858R/T790M, and HER2, respectively. Afatinib can be used in the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer.